NFKB1 and neoplasm: NF-κB inhibition can downregulate B-cell lymphoma 2 (BCL-2), thus enhancing the susceptibility of tumor cells to programmed cell death and rendering them more receptive to the potent effects of chemotherapy drugs [21].